Hildron Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.25 M
- Company Age 29 Year, 5 Months
- Last Filing with ROC 31 Mar 2010
- Open Charges ₹ 2.02 M
About Hildron Pharmaceuticals
Hildron Pharmaceuticals Limited (HPL) is a Public Limited Indian Non-Government Company incorporated in India on 12 September 1995 and has a history of 29 years and five months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2010. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.25 M.
The company currently has active open charges totaling ₹2.02 M.
Tukaram Surba, Shilesh Harmalkar, and Prashant Mayekar serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1995PLC092607
-
Company No.
092607
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
12 Sep 1995
-
Date of AGM
24 Sep 2010
-
Date of Balance Sheet
31 Mar 2010
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Hildron Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tukaram Surba
|
Director | 12-Sep-1995 | Current |
|
Shilesh Harmalkar
|
Director | 06-Sep-2006 | Current |
|
Prashant Mayekar
|
Director | 06-Sep-2006 | Current |
Financial Performance of Hildron Pharmaceuticals.
Enhance accessibility to Hildron Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hildron Pharmaceuticals?
Unlock access to Hildron Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Federation Of Small Scale Pharma Industries Of IndiaTukaram Surba is a mutual person
Charges (Loans)
₹2.02 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Maharashtra : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Mar 2000 | Bank Of Maharashtra | ₹0.72 M | Open |
| 10 May 1999 | Bank Of Maharashtra | ₹1.30 M | Open |
How Many Employees Work at Hildron Pharmaceuticals?
Unlock and access historical data on people associated with Hildron Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hildron Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hildron Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.